latest research, page-9

SLA will be a very profitable company in the future - I have little doubt about that. Sure there will be obstacles and we have not disregarded these. I just really like how SLA have gone about resolving these issues.

There is no questioning where SLA is sitting atm... it is at the brink of being cash flow positive i.e. it is at 'the' transition stage of an R&D coy... to a cash generating machine. Approval was the hurdle that needed clearing for this to occur.. and SLA were ready to hit the ground running. The first obstacle after Approval (if that wasnt a big enough obstacle to cross) is to get the manufacturing facilities up and running to cope with demand. SLA have planned ahead and acquired SibeX, and are in negotiations on another acquisition on top of the exisiting upgrades planned.

Do not forget that Ropren (BioR) is but ONE of the dozens of bioeffectives that will be generating money in the short, mid and long term.

There is method in this madness... those who see value accumulate.